Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nalbuphine Extended-Release Tablets for the Treatment of Chronic Cough in Participants With Idiopathic Pulmonary Fibrosis

NCT07671911 is registered in ClinicalTrials.gov with Trevi Therapeutics as lead sponsor.

NCT NCT07671911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07671911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nalbuphine Extended-Release Tablets for the Treatment of Chronic Cough in Participants With Idiopathic Pulmonary Fibrosis
Lead sponsor
Trevi Therapeutics
Phase
Phase 3
Overall status
Recruiting
Start date
June 29, 2026
Completion date
July 31, 2028
Enrollment
306 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis